OncoSec Medical
OncoSec Medical
Employees:
40
Market Cap:
$60.94 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-26.98 million
Stock:
ONCS
OncoSec Medical
Are you from OncoSec Medical?
Employees:
40
Market Cap:
$60.94 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-26.98 million
Stock:
ONCS
  • #DYK ImmunoPulseIL-12 + #pembrolizumab in anti-PD-1 non-responsive patients led to a 50% best overall response rate: http://bit.ly/2C9pjIi
  • Were proud of the progress weve made to advance OncoSecs science and technology. Check out our recent scientific posters from #SITC2017 at http://bit.ly/1KKQHcq
  • We are pleased to announce updated data from our combination study (Phase 2 OMS-I102) of ImmunoPulse IL-12 in combination with pembrolizumab, which demonstrated a 57% Progression Free Survival Rate at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients! "Overall, the Phase 2 trial results, including progression free survival beyond two years in multiple patients, duration of response, best overall response rate, and tolerability of the combination, provide a strong and consistent theme across multiple endpoints, underscoring the promise of ImmunoPulse IL-12 plus pembrolizumab as a viable treatment option for patients diagnosed with metastatic melanoma," said Dr. Alain Algazi, Lead Trial Investigator, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. These results will be presented in an oral presentation on Friday, November 10th, 2017 at the Society for Immunotherapy of Cancer Annual Meeting. Click here for more details: http://bit.ly/2zrapOu
  • Breast Cancer affects many lives. Talk to your doctor about screening, family history and prevention today! #breastcancerawarenessmonth

#DYK ImmunoPulseIL-12 + #pembrolizumab in anti-PD-1 non-responsive patients led to a 50% best overall response rate: http://bit.ly/2C9pjIi

Were proud of the progress weve made to advance OncoSecs science and technology. Check out our recent scientific posters from #SITC2017 at http://bit.ly/1KKQHcq

We are pleased to announce updated data from our combination study (Phase 2 OMS-I102) of ImmunoPulse IL-12 in combination with pembrolizumab, which demonstrated a 57% Progression Free Survival Rate at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients! "Overall, the Phase 2 trial results, including progression free survival beyond two years in multiple patients, duration of response, best overall response rate, and tolerability of the combination, provide a strong and consistent theme across multiple endpoints, underscoring the promise of ImmunoPulse IL-12 plus pembrolizumab as a viable treatment option for patients diagnosed with metastatic melanoma," said Dr. Alain Algazi, Lead Trial Investigator, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. These results will be presented in an oral presentation on Friday, November 10th, 2017 at the Society for Immunotherapy of Cancer Annual Meeting. Click here for more details: http://bit.ly/2zrapOu

Breast Cancer affects many lives. Talk to your doctor about screening, family history and prevention today! #breastcancerawarenessmonth

Jobs at at OncoSec Medical

There are no jobs at the current time